The ALS Ltd (ASX: ALQ) share price is in focus today after the company reported record FY26 results, highlighted by 10.7% revenue growth to $3.32 billion and a 25.8% boost in underlying NPAT to $381.2 million.
What did ALS report?
- Revenue rose 10.7% year on year to $3.32 billion
- Underlying net profit after tax (NPAT) jumped 25.8% to $381.2 million
- Underlying EBIT increased 19.3% to $599.0 million; margin improved 129 bps to 18.0%
- Statutory NPAT was $318.7 million â up 24.4% on last year
- Free cash flow of $674.1 million, with EBITDA cash conversion at 92%
- Final dividend of 23.1 cents per share (partially franked), taking full year DPS to 42.5 cents
What else do investors need to know?
ALS delivered strong organic growth in its Commodities division, with revenue up 18.8%, mainly from increased mineral exploration activity. The Life Sciences division grew revenue by 6%, led by strong performance in its Food business, while Environmental saw softer conditions in the Americas due to both internal and market challenges, which are now being addressed.
The company’s balance sheet strengthened with financial leverage reduced to 1.5x, below its desired range, thanks to solid cash generation and a successful equity raising. ALS also invested heavily in four new hub laboratories across Minerals and Environmental, underpinning future growth. The company continues to deliver industry-leading safety outcomes.
What did ALS management say?
CEO and Managing Director Malcolm Deane, said:
ALS has delivered robust financial performance in FY26, reflecting the resilience of our diversified portfolio, disciplined operational execution and the commitment of our people in continuing to deliver high quality service and outcomes for our customers. Throughout the year, we remained focused on executing our refreshed strategy and advancing the priorities outlined in our value creation framework. This included disciplined capital allocation, targeted investment in growth opportunities and ongoing portfolio optimisation to strengthen returns and position the business for long-term sustainable growth, maximising shareholder returns.
What’s next for ALS?
ALS expects to continue mid to high single-digit organic revenue growth in FY27, with further margin expansion planned. Its new Sydney and Lima laboratories are set to be commissioned in H2 FY27, boosting capacity in key areas. The group also plans to deliver tangible benefits from its Lab of the Future initiative, investing in automation, digital infrastructure and AI.
Management is staying alert to global macro and supply chain risks, but a strong balance sheet positions ALS to pursue organic and inorganic growth. Minerals and Industrial Materials divisions are tipped for double-digit and high single-digit growth, respectively, while Life Sciences aims for improved mid-single-digit organic growth.
ALS share price snapshot
Over the past 12 months, ALS shares have risen 25%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
The post ALS reports record FY26 earnings and dividend uplift appeared first on The Motley Fool Australia.
Should you invest $1,000 in Als right now?
Before you buy Als shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Als wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Pro Medicus inks $90m contract
- Brambles revises FY26 outlook, announces new US$400m buy-back
- Elders posts higher HY26 profit and holds interim dividend
- Life360 launches US$225m share repurchase to offset dilution
- What on earth’s going on with Xero shares?
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.